Strategic Integration of Generative AI: Opportunities, Challenges, and Organizational Impacts
Law, Economics and Society · 2025
DOI: 10.30560/les.v1n1p156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Law, Economics and Society, 2025. Verfasst von Gregory K. Smith. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Generative Artificial Intelligence (GenAI) is reshaping modern business operations, offering transformative capabilities in automation, content creation, and data-driven decision-making. However, adopting GenAI is not without challenges, particularly regarding governance, cybersecurity, ethical concerns, and workforce adaptation. This paper explores how pilot programs are essential for integrating GenAI into business operations while mitigating associated risks. Drawing on a narrative literature review, this study synthesizes contemporary research, industry best practices, and case studies to analyze adoption strategies, regulatory frameworks, and governance models. The findings emphasize the necessity of structured AI governance, organizational preparedness, and iterative testing to ensure successful GenAI deployment. By contributing to the broader discussion on AI’s role in business strategy, this study provides practical recommendations for organizations aiming to implement GenAI ethically, securely, and efficiently.
Zitieren
APA
Smith, G. K. (2025). Strategic Integration of Generative AI: Opportunities, Challenges, and Organizational Impacts. Law, Economics and Society. https://doi.org/10.30560/les.v1n1p156
Vancouver
Smith GK. Strategic Integration of Generative AI: Opportunities, Challenges, and Organizational Impacts. Law, Economics and Society. 2025. doi:10.30560/les.v1n1p156
BibTeX
@article{Smith2025,
author = {Smith, Gregory K.},
title = {Strategic Integration of Generative AI: Opportunities, Challenges, and Organizational Impacts},
journal = {Law, Economics and Society},
year = {2025},
doi = {10.30560/les.v1n1p156}
}
EUVIMED